Clinical Trial Update: A 36-Week Extension to Protocol ISA04-03 [Phase 3]

View source ↗

Summary

This document reports a 36-week extension to the Phase 3 ISA04-03 trial in psoriasis and notes that the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Snippet

Sponsor: Aurinia Pharmaceuticals Inc. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED